This early-stage study is testing a new radioactive tracer called TRDC002 to see if it can help doctors better locate prostate cancer that has returned or spread. The study will enroll 6 men with this type of cancer to see which dose and timing gives the clearest scan images. Res…
Phase: PHASE1 • Sponsor: C Ray Therapeutics • Aim: Diagnosis
Last updated Mar 31, 2026 12:11 UTC